FDA — authorised 17 September 2001
- Marketing authorisation holder: AMGEN
- Status: approved
🇺🇸 Aranesp in United States
FDA authorised Aranesp on 17 September 2001
Marketing authorisations
FDA — authorised 17 September 2001
- Application: BLA103951
- Marketing authorisation holder: AMGEN
- Local brand name: ARANESP
- Indication: VIAL — INTRAVENOUS
- Status: approved
Aranesp in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Aranesp approved in United States?
Yes. FDA authorised it on 17 September 2001; FDA authorised it on 17 September 2001.
Who is the marketing authorisation holder for Aranesp in United States?
AMGEN holds the US marketing authorisation.